Temferon
Phase 1/2Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma Multiforme
Conditions
Glioblastoma Multiforme
Trial Timeline
Mar 5, 2019 → Jun 30, 2026
NCT ID
NCT03866109About Temferon
Temferon is a phase 1/2 stage product being developed by Genenta Science for Glioblastoma Multiforme. The current trial status is active. This product is registered under clinical trial identifier NCT03866109. Target conditions include Glioblastoma Multiforme.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03875495 | Phase 1/2 | Terminated |
| NCT03866109 | Phase 1/2 | Active |
Competing Products
20 competing products in Glioblastoma Multiforme